Clinical Trial

Atorvastatin to Reduce Inflammation After Tuberculosis Treatment Completion

Study acronym: StatinTB
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated August 23, 2024 (before its estimated September 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a proof-of-concept phase IIB, double-blind, randomized, placebo-controlled trial to evaluate the safety and efficacy of 40 mg atorvastatin to reduce persistent lung inflammation after successful TB treatment completion in HIV-infected and HIV-uninfected adults measured by PET/CT.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2019-10-29; most recent amendment 2024-08-22.
Status change: Not Yet Recruiting → Recruiting 2020-11-16
Trial Details
NCT Number NCT04147286
Lead Sponsor University of Cape Town
Collaborators: University of Zurich, University of Namibia, University of Bern, University of Stellenbosch
Conditions Tuberculosis, Pulmonary
Enrollment 220 participants
Start Date 2020-07-14
Primary Completion 2025-09-30 (estimated)
Study Completion 2027-09-30 (estimated)
Updated on ClinicalTrials.gov 2024-08-23